IQVIA’s dynamic HCP profiling and targeting solutions leverage AI/ML to enhance patient identification, treatment transitions, and adherence strategies. For asthma, predictive models improved targeting of uncontrolled patients by 30%, reducing uncontrolled disease by 17% in six months. In biologics, alerts precision increased fivefold, boosting patient transitions to therapy. Oncology and autoimmune models predicted treatment switches with up to 15x higher accuracy and drove earlier adoption. Rare disease models outperformed rules-based methods by up to 95x. Overall, these approaches improved outcomes, optimized salesforce focus, and accelerated therapy uptake.

Join for free to read